SUSAN HOLLE-UTLEY: Open Payments
NPI 1144627373 · SUGAR LAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$943 in 46 payments from 13 companies in 2025. Trend: 2023 $733 · 2024 $852 · 2025 $943
Food & beverage: $943
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 7 | $172 |
| Amgen Inc. | 10 | $163 |
| AstraZeneca Pharmaceuticals LP | 7 | $116 |
| Merck Sharp & Dohme LLC | 5 | $102 |
| Boston Scientific Corporation | 4 | $87 |
| ABIOMED | 1 | $73 |
| Novo Nordisk Inc | 3 | $57 |
| HEARTFLOW, INC. | 3 | $51 |
| Abbott Laboratories | 2 | $46 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
Products named: LEQVIO, REPATHA, FARXIGA, WATCHMAN FLX, VERQUVO, FFRct, CARDIOMEMS, CAMZYOS.
Industry payments across TX — which companies pay providers there.
